Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Tislelizumab Combined With Platinum-containing Drug Chemotherapy in First-line Treatment of Lung Adenocarcinoma With Asymptomatic Brain Metastatic

NCT06056115 is registered in ClinicalTrials.gov with Hebei Medical University Fourth Hospital as lead sponsor.

NCT NCT06056115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06056115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Tislelizumab Combined With Platinum-containing Drug Chemotherapy in First-line Treatment of Lung Adenocarcinoma With Asymptomatic Brain Metastatic
Lead sponsor
Hebei Medical University Fourth Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
May 1, 2023
Completion date
December 12, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung adenocarcinoma